Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE:DRREDDY)(NYSE: RDY) reported on Thursday the availability of Albendazole Tablets, USP in the US market.
The company added the US Food and Drug Administration (USFDA) approved Albendazole Tablets, USP is a therapeutic equivalent generic version of Albenza Tablets in 200mg in bottle count sizes of two. Albenza is a trademark of Glaxosmithkline.
For the most recent 12 months ending in November 2020, the Albenza brand and generic had US sales of approximately USD27m MAT, according to IQVIA Health.
lbendazole (albendazolum) is an oral medication used for the treatment of a variety of parasitic worm infestations. It is useful for giardiasis, trichuriasis, filariasis, neurocysticercosis, hydatid disease, pinworm disease and ascariasis, among other diseases, concluded the company.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling